Research & Drug Development

F. Stocchi 1, L. Vacca 1, G. Battaglia 1, P. Grassini 1, S Ruggirei 1, A. Thomas 2, M. Onofrj 2
Clinical evidence of efficacy for safinamide
1 IRCCS Neuromed, Pozzilli, Italy; 2 University G. DAnnunzio, Chieti, Italy 7th International Congress AD/PD 2005 Sorrento 9-12 March

T.C. Stummann, P. Salvati, R.G Fariello, L. Faravelli
The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons.
Eur J Pharmacol. 2005 Mar 14;510(3): 197-208.

C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, P. Salvati, RG Fariello
Safinamide: from molecular targets to a new antiparkinson drug
7th International Congress AD/PD 2005 Sorrento 9-12 March

E. Perucca; M. Onofrj; A. Thomas; C. Cattaneo; RG Fariello
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (Eilat VII)
Epilepsy Res. 2004 Sep-Oct; 61 (1-3): 12-14

Cibele Sabido-David, L. Faravelli, P. Salvati
The therapeutic potential of sodium and calcium channel blockers in pain management
Expert Opin Investig Drugs 2004 Oct.: 13(10) 1249-61

O. Veneroni, E. Izzo, G. Graziani, S. Parini, L. Dho, P. Salvati
Antiallodynic effect of ralfinamide in spinal nerve ligation rat model of neuropathic pain
XXXth Annual Meeting Society for Neuroscience, San Diego, CA (USA), October 23-27, 2004

E. Izzo,O. Veneroni, G. Graziani, P. Paudice, M. Raiteri, P. Salvati
Anti-inflammatory effect of ralfinamide on carraggeenan-induced paw oedema in rat and on spinal cord synaptosomes substance P release
XXXth Annual Meeting Society for Neuroscience, San Diego, CA (USA), October 23-27, 2004

C. Besana; S. Rossetti; C. Cattaneo
Significant improvement of motor function in early Parkinson Disease (PD) with safinamide
13th International Conference on Pharmaceutical Medicine Ginevra 19/22 September - 2004

L. Leonetti; P. Salvati; C. Caccia; A. Carotti
Sintesi su fase solida della safinamide e suoi analoghi
XVII Convegno Nazionale della Divisione di Chimica Farmaceutica della Società Chmica Italiana Pisa, 6-10 Settembre - 2004

F. Stocchi; G. Arnold; M. Onofrj; H. Kwiecinski; A Szczudlik; A. Thomas; U. Bonuccelli; A. Van Dijk; C. Cattaneo; P. Sala; R. Fariello
Improvement of motor function in early Parkinson Disease by Safinamide
Neurology August 2004; 63

A. Restivo; S. Francisconi; T. Stummann; L Faravelli; C. Sabido David; C. Caccia
Functional fluorescent cell based assays for screening ion channel targets
4th Forum of European Neuroscience Lisbon, Portugal, 10-14 July - 2004 FENS Abstr.; Vol.2 , A012.18 - 2004

A. Marzo; L. Dal Bo; N. Ceppi Monti; F. Crivelli; S. Ismaili; C. Caccia; C. Cattaneo; R. Fariello
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
Pharmalogical Research, Volume 50, Issue 1, July 2004, Pages 77-85

A. Thomas; C. Cattaneo; C. Besana; P. Sala; M. Onofrj; M. Baratti; G. Nordera; T. Mesiano; G. Fabbrini; P. Barbanti; R. Fariello
Funzionalità motoria: follow-up su pazienti parkinsoniani in precedenza trattati con safinamide
XXX Congresso Nazionale LIMPE Pescara, 19/21 Novembre - 2003

M. Onofrj; C. Cattaneo; F. Stocchi; L. Vacca; A.Thomas; R. Fariello
Safinamide migliora la funzionalità motoria in pazienti parkinsoniani
XXX Congresso Nazionale LIMPE Pescara, 19/21 Novembre - 2003

C.T. Chung; P. Guidetti; E. Izzo; F.J.Denaro; O. Jones; J.L. Bryant; R. Schwarcz
Slowly evolving increase in brain quinolinic acid levels in a HIV-1 transgenic rat
33rd Annual meeting Society for Neuroscience New Orleans, November 8-12 - 2003

M. Woltz; M. Muller; C. Leuratti; C. Cattaneo; R. Fariello
First dose in man of ralfinamide, a new CNS drug with central analgesic effect
XXXIV Congresso Società Italiana di Neurologia - SIN Roma, 11-15 October 2003

T. Stummann; P. Salvati; R. Fariello; L. Faravelli
NW-1029, an alpha-aminoamide derivative with antihuperalgesic and antiallodynic properties inhibits NA+ currents in rat sensory neurons
4th Congress of EFIC - Prague, Czech Republic, September 2-6, 2003

Salvati P.; Faravelli L.; Veneroni O.
TTX-sensitive and TTX-resistant sodium channels
226th ACS National Meeting New York, 7-11 September 2003

Girola L.; Salvati P.; Caccia C.
Amyloid Beta1-42 spontaneous aggregation: a suitable "slow" process to detect compounds interfering with amyloid fibril formation
SINS 2003, Pisa, 26-28 September

Restivo A.; Maestroni S.; Fariello R.G.; Salvati P.; Caccia C.
Involvement of mitogen-activated protein kinases in oxidative stress-induced cell death in human SH-SY5Y neuroblastoma cells
SINS 2003, Pisa, 26-28 September

Curatolo L.; Izzo E.; Caccia C.; Dho L.; Lamberti E.; Parini S.; Salvati P.
Role of Kynurenine pathway in an in vitro model of cataract
SINS, 2003-Pisa, 26-28 September

Izzo E.; Carpened R.; Cozzi A.; Cipriani G.; Veneroni O.; Moroni F.
Effects of Kynurenine 3-mono-oxygenase Inhibitors on Learning and Memory and Glutamate Release in Different Rat Brain Areas.
Neuroscience New Orleans, USA 8-12 November, 2003

Curatolo L.; Faravelli L.; Caccia C.; Salvati P.
Ion Channel as a Therapeutic Target for Neuroprotection:safinamide.
Neurotox 2003 Nottingham, UK UK 1-4 September

Faravelli L.; Fariello R.G.; Salvati P.;
Inhibition of TTXr Na+currents in Rat Sensory Neurons by NW-1029, a New Antihyperalgesic Agent.
Proceeding of the 10th Congress on Pain, Progress in Pain Research and Management ( 2003) Vol. 24:115-124

Veneroni O.; Maj R.; Calabresi M.; Faravelli L.; Fariello R.G.; Salvati P.
Antiallodynic Effect of NW-1029, a Novel Na+Chanel Blocker In Experimental Animal Models of Inflammatory and Neuropathic Pain.
Pain 102, 17-25, 2003

Veneroni O.; Faravelli L.; Calabresi M.; Maj R.; Fariello R.G.; Salvati P.
NW-1029: a Potent Na+Channel Blocker in Animal Models of Inflammatory and Neurtopathic Pain.
XXXIIth Annual Meeting of the Society of Neuroscience, Orlando, Florida USA, November 2-7, 2002

Veneroni O.; Maj R.; Calabresi M.; Fariello R.G.; Salvati P. (SPON. Biella G.)
Antihyperalgesic Effect of NW-1029, a Novel Na+Channel Blocker in Animal Models of Inflammatory and Neuropatic Pain.
10th World Congress on Pain, San Diego CA, USA, August 17-22, 2002

Zecca L.; Fariello R.G.; Riederer P.; Sulzer D.; Gatti A.; Tampellini D.
The Absolute Concentration of Nigral Neuromelanin, Assayed by a New Sensitive Method, Increases Throughout the Life and is Dramatically Decreased in Parkinson's Disease.
FEBS Lett.; 510(3): 216-20, 2002

Zecca L.; Tampellini D.; Gerlach M.; Riederer P.; Fariello R.G.; Sulzer D.
Substantia Nigra Neuromelanin: Structure, Synthesis and Molecular Behaviour.
Mol. Pathol., 54(6): 414-8, 2001

Veneroni O.; Maj R.; Calabresi M.; Fariello R.G.; Benatti L.; Salvati P.
NW-1029, a Novel Na+Channel Blocker Is Effective in Animal Models of Chronic Pain.
Italian Pharmacology Society, Pharmacological Research, 43, SUP A26 2001

Salvati P.; Caccia C.; Maj R.; Musanti R.; Lamberti E.; Calabresi M.; Benatti L.; Fariello R.G.
NW-1048 is a Novel, Reversible and Selective MAO-B Inhibitor with Neuroprotective Effects in a Model of Parkinson's Disease.
30th Neuroscience Conference New Orleans, 2000

Faravelli L.; Maj R.; Veneroni O.; Fariello R.G.; Benatti L.; Salvati P.;
NW-1029 Is a Novel Na+Channel Blocker with Analgesic Activity in Animal Models.
Soc. for Neuroscience, Abs,26 (1): 1218, 2000

Marzo A.; Dal Bo L.; Crivelli F.; Ceppi Monti N.; Ismaili S.; Fariello R.G.; Uhr M.R.;
Pharmacokinetics, Pharmacodynamics and Tolerability of NW-1015, a New Anticonvulsant Agent.
5th Eilat Conference on New Antiepileptic Drugs, 2000

Fariello R.G.; Maj R.; Caccia C.; Benatti L.; Salvati P.
NW-1015 a Novel Potential Antiepileptic Drug: Preclinical and Early Clinical Development.
5th Eilat Conference on New Antiepileptic Drugs, 2000

Fariello R.G.; Maj R.; Marrari P.; Pevarello P.; Beard D.; Algate C.; Post C.; Salvati P.
Acute Behavioral and EEG Effects of NW-1015 on Electrically-Induced Afterdischarge in Conscious Monkeys.
Epilepsy Res., 39: 37-46, 2000

Schafer M.; Schwaeble W.J.; Post C.; Salvati P.; Calabresi M.; Sim R.B.; Petry F.; Loos M.; Weihe E.
Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia.
Journal Immunology, 164, 2000

Salvati P.; Maj R.; Caccia C.; Cervini M.A.; Lamberti E.; Pevarello P.; Skeen G.A.; White H.S.; Wolf H.H.; Faravelli L.; Mazzanti M.; Mancinelli E.; Varasi M.; Fariello R.G.
Biochemical and Electrophysiological Studies on the Mechanism of Action of PNU-151774E, a Novel Antiepileptic Compound.
J.Pharmac.Exp. Ther.; 288: 1151-1159, 1999

Maj R.; Fariello R.G.; Pevarello P.; Varasi M.; McArthur R.A.; Salvati P.
Anticonvulsant Activity of PNU-151774E in the Amygdala Kindled Model of Complex Partial Seizures.
Epilepsia, 40: 1523-1528, 1999

Pevarello P.; Traquandi G.; Bonsignori A.; McArthur R.A.; Maj R.; Caccia C.; Salvati P.; Varasi M.
Synthesis and Preliminary Biological Evaluation of New a-Amino Amide Anticonvulsants Incorporating a Dextromethorphan Moiety.
Biorg. Med.Lett., 9:1783-1788, 1999

Pevarello P.; Bonsignori A.; Caccia C.; Amici R.; McArthur R.A.; Fariello R.G.; Salvati P.; Varasi M.
Sodium Channel Activity and Sigma Binding of Enantiomeric 2-Aminopropanamide Anticonvulsants.
Biorg. Med. Lett.; 9:2512-2524, 1999

Salvati P.; Maj R.; McArthur R.A.; Cervini M.A.; Kozak W.; Benatti L.; Fariello R.G.
PNU-151774E, a Novel Na+Channel Blocker, Shows Analgesic Effects in Some Animal Models.
Soc. for Neuroscience, Abs 25(2): 1947, 1999

Maj R.; Calabresi M.; Caccia C.; Salvati P.; Fariello R.G.
PNU-151774E, A Combined MAO-B and Glutamate Release Inhibitor, is Effective in Animal Models of Parkinson's Disease
Soc. for Neuroscience, Abs, 25(2): 1599, 1999

Maj R.; Fariello R.G.; Ukmar G.; Varasi M.; Pevarello P.; McArthur R.A.;Salvati P.
PNU-151774E Protects Against Kainate-Induced Status Epilepticus and Hippocampal Lesions in the Rat.
Eur.; J. Pharmacol.; 359: 27-32, 1998

Pevarello P.; Bonsignori A.; Dostert P.; Heidempergher F., Pinciroli V.; Colombo M.; McArthur R.A.; Salvati P.; Fariello R.G.; Varasi M.
Synthesis and Anticonvulsant Activity of a New Class of 2-((Arylalkyl) Amino) Alkamide Derivatives.
J. Med. Chem.; 41: 579-590, 1998

Fariello R.G.; McArthur R.A.; Bonsignori A.; Cervini M.A.; Maj R.; Marrari P.; Pevarello P.; Wolf H.H.; Woodhead J.W.; White H.S.; Varasi M.; Salvati P.; Post C.
Preclinical Evaluation pf PNU-151774E as a Novel Anticonvulsant
J. Pharmac.Exp. Ther. 285: 397-403, 1998

Strolin Benedetti M., Tocchetti P., Rocchetti M., Martignoni M., Marrari P., Poggesi I. and Doster P.
Enatioselective Recognition of Two Anticonvultants, FCE 26743 and FCE 28073 by MAO, and Relationship Between MAO-B Inhibition and FCE 26743 Concentrations in Rat Brain.
Progress in Brain Res., 106: 123-134, 1995

Strolin Benedetti M.; Marrari P.; Colombo M.; Castelli M.G.; Arand M.; Oesch F and Dostert P.
The Anticonvulsant FCE 26743 Is a Selective and Short-Acting MAO-B Inhibitor Devoid of Inducing Properties Towards Cytochrome P450-Dependent Testosterone Hydroxylation in Mice and Rats
J. Pharm. Pharmacol.; 46: 814-819, 1994